# Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct04390399/  
OnCo record `nct04390399` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Nogapendekin alfa inbakicept, Aldoxorubicin, Gemcitabine and Cyclophosphamide in pancreatic ductal adenocarcinoma, run by ImmunityBio, Inc., active and no longer recruiting.

## Summary

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer is a phase 2 interventional study registered as NCT04390399 by ImmunityBio, Inc., with 328 participants enrolled, started 2020-07-21 and due to reach its primary completion in 2025-10-13. Interventions recorded: N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine and Cyclophosphamide.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04390399
- Phase: 2
- Setting: Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-care Chemotherapy Versus Standard-of-care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
- Sponsor: ImmunityBio, Inc.
- Enrolled: 328

## Sources

- ClinicalTrials.gov NCT04390399: https://clinicaltrials.gov/study/NCT04390399

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Aldoxorubicin](https://onco.cc/drugs/aldoxorubicin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nogapendekin alfa inbakicept](https://onco.cc/drugs/nogapendekin-alfa/)
- companies: [ImmunityBio](https://onco.cc/companies/immunitybio/)

---
JSON: https://onco.cc/api/v1/entities/nct04390399.json